

Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!

Ragavendra R. Baliga^{1*}, Eric H. Yang², and Eduardo Bossone³

¹Division of Cardiovascular Medicine, The Ohio State Wexner Medical Center, Columbus, OH, USA; ²Division of Cardiology, Department of Medicine, UCLA Medical Center, University of California at Los Angeles, Los Angeles, CA, USA; and ³Division of Cardiology, Internal Medicine Department, A. Cardarelli Hospital, Via Cardarelli 9, Naples - 80131, Italy

The residual risk of cardiovascular disease is ~50–60% despite intensive LDL-cholesterol lowering with statins and ezetimibe, prompting investigation into therapies that elevate HDL-cholesterol.^{1–3} Earlier studies suggested that the risk of atherosclerotic disease has a linear relationship with HDL-C levels. One meta-analysis reported that for every 1 mg/dL increase in HDL-C there is a 2% decrease in risk of coronary heart disease in men and 3% decrease in women.⁴ Based on an elderly cohort of the Framingham Heart Study, it was⁵ estimated that every change of 10 mg/dL in HDL-C is associated with a 50% change in risk.⁶ Given this strong inverse linear relationship between cardiovascular risk and HDL levels, the New Zealand guidelines group⁷ incorporated HDL-C levels in the assessment of cardiovascular risk. However, attempts to increase HDL-C with pharmacotherapy has not been associated with improved outcomes,⁸ particularly in patients whom significant risk reduction has already been achieved with LDL-C lowering.⁹ Cholesterol ester transfer protein inhibitors have either neutral, very small or negative, effects on cardiovascular outcomes.^{10–13} Similarly, studies of niacin and fibrates have had disparate outcomes.^{5,8,14,15} Newer treatments, including anti-protein convertase subtilisin/kexin type 9 monoclonal antibodies have resulted in modest increases in HDL-C levels—up to 7.6% in one meta-analysis of 25 trials—but with more dramatic reductions of over 50% in LDL-C levels driving decreased major cardiovascular events in some studies.¹⁶ In addition, studies utilizing Mendelian randomization have shown no direct relation between genetically determined HDL-C concentrations and cardiovascular events.^{17–19} While low HDL-C levels in the absence of hypertriglyceridaemia have been associated with increased cardiovascular risk and primary lipid disorders such as ApoA-I deficiency, they may be reflective of underlying disease states, certain medication use (i.e. anabolic steroids, fibrates), impact of type of exercise (aerobic vs. isometric),²⁰ and malignancy.²¹ On the other end of the spectrum, there are reports suggesting that very high HDL-C levels adversely impacts survival.^{22,23} Emerging

evidence suggests that the relationship between cardiovascular risk and HDL-C levels is not linear and may even be U-shaped.²²

It has been argued that this so-called HDL paradox stems from a progressive mistaken discernment between HDL and HDL-C.²⁴ These authors contend that the 1975 Gofman–Miller^{25–27} hypothesis stating that ‘a reduction in plasma-HDL may impair the normal clearance of cholesterol from the arterial wall and thereby accelerate the development of atherosclerosis’ refers to HDL particle number. But given that HDL particle number could not be measured, HDL concentration became the surrogate measurement and subsequently as a result of widespread public acceptance clinical HDL concentration became commonplace. As a result, with time, clinicians and clinical investigators began to pursue ways in which HDL concentration could be elevated to reduce cardiovascular risk.

In their paper Zhong *et al.*²⁸ report a meta-analysis of 37 prospective cohort studies, involving 3 524 505 participants and more than 612 027 deaths, to evaluate the association between HDL-C levels and mortality. They found HDL-C level was found to be associated with mortality from all causes, cardiovascular disease (CVD), and cancer in a J-shaped dose–response pattern, with the lowest risk observed at HDL-C levels of 1.40–1.50 mmol/L, 1.75–1.85 mmol/L, and 1.65–1.75 mmol/L, respectively. Compared with HDL-C level of 1.45 mmol/L, the pooled hazard ratios (HRs) for all-cause mortality were 1.12 [95% confidence interval (CI) 1.04–1.21] and 1.47 (95% CI 1.39–55) for each 1 mmol/L increase and decrease in HDL-C levels, respectively. Moreover, the pooled HRs for all-cause mortality were 1.21 (95% CI 1.09–1.36) and 1.36 (95% CI 1.21–1.53) for the highest and the lowest categories of HDL-C levels, respectively. Therefore, HDL-C level is associated mortality from all causes, CVD, and cancer in a J-shaped dose–response manner, that is, both extremely high and low HDL-C levels are associated with an increased risk of mortality. The findings of this meta-analysis are supported by the fact that other studies have also shown that individuals with very high HDL




Figure 1 Schematic representation of lipid transport as a metro system. The HDL transport system (blue line) can be likened to a series of heterogeneous protein trains carrying a diverse group of lipid passengers (different lipid species indicated by various shapes and colours of passengers) through the circulatory system. As HDL trains travel through the circulatory system, lipid passengers embark and disembark at various stations [peripheral tissues (white rectangles and square)]. Lipid passengers can also move between circulating cells and lipoproteins [including LDLs (on the green line) and very low density lipoprotein (VLDLs) (not shown)]. The net direction of lipid movement associated with HDL is uptake from peripheral tissues and transport to the liver, which in arteries prevents proatherogenic lipid accumulation. In this analogy, the liver is the central station, where most lipid passengers disembark and previously lipid-laden HDL trains can be recycled and recirculated. The liver is also a hub of HDL production, forming nascent HDL particles that are lipid-poor and avid acceptors of peripheral lipids.²⁴

cholesterol^{22,23} or high ratio of HDL cholesterol to particle number²⁹ have increased morbidity and mortality burden of atherosclerosis. To explain these results Xiang and Kingwell²⁴ and Feng et al.³⁰ argue that HDL-C is essentially a snapshot, a static measure, of the dynamic process of HDL particle transport and nor does it reflect particle function²⁴ (Figure 1). Feng et al. proposed that the reserve remnant cholesterol transport hypothesis wherein HDL acquires triglyceride-rich lipoproteins upon lipolysis with subsequent transport of remnant-derived cholesterol to the liver in a pathway which originates in the intestine with secretion of ApoA-1 on chylomicrons followed by transport to plasma via lymph. To assess this hypothesis they developed a novel *in vitro* fluorescent assay to evaluate the capacity of HDL to acquire free cholesterol from triglyceride-rich lipoproteins during lipolysis by lipoprotein lipase. They applied this assay to several groups of subjects with markedly different HDL-C levels. Their findings revealed that decrease free cholesterol transfer from triglyceride-rich lipoproteins to HDL in subjects with both low and extremely high HDL-C. These investigators conclude that these findings are probably a link between HDL-associated cardiovascular risk to triglyceride metabolism and account for U-shape relationship of HDL-C and cardiovascular disease. These findings are in important advance in the dynamics of HDL-C transport. The next step would be to determine whether this assay can predict linear cardiovascular risk. The fact that much is yet to be learnt about HDL-C transport should not be viewed as a drawback, instead it heralds a golden opportunity for life scientists and clinical investigators to work closely together to expand our understanding of this complex phenomenon. Recent advancements in 'omics' including at the molecular gene level

(genomics: the study of genes and their function), the protein level (proteomics: the study of proteins), the transcript level (transcriptomic: the study of all RNA molecules, including non-coding RNAs), and the metabolic level (metabolomics: the study of molecules involved in cellular metabolism) raise the possibility that more accurate biomarkers of HDL-C transport system, such as the novel assay developed by Feng et al.,³⁰ rather than HDL-C test could be developed. These include HDL particle number, functionally significant structural components and function, as well as cholesterol efflux capacity (the first step in reverse cholesterol transport) with the hope that they could more accurately predict future cardiovascular risk, and to guide and monitor therapy. Until then, HDL-C remains a useful risk marker to predict cardiovascular risk but with the caveat that the association is curvilinear—that is, it is not straightforward!

Conflict of interest: none declared.

References

- Baliga RR. HDL-cholesterol: perfection is the enemy of good? *Med Clin North Am* 2012;**96**:27–37.
- Baliga RR, Cannon CP. *Dyslipidemia*. Oxford; New York: Oxford University Press; 2012.
- Baliga RR. *Statin Prescribing Guide*. Oxford New York: Oxford University Press; 2010.
- Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation* 1989;**79**: 8–15.
- AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011;**365**:2255–2267.

6. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. *Am J Cardiol* 1983;**52**:9B–12B.
7. Group NZG. *New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners*. Wellington, New Zealand: New Zealand Guidelines Group; 2009.
8. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ* 2014;**349**:g4379.
9. Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). *Circulation* 2005;**112**:3058–3065.
10. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon J, Mosca L, Tardif J-C, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med* 2007;**357**:2109–2122.
11. HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;**377**:1217–1227.
12. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlan E, Wolksi K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. *N Engl J Med* 2017;**376**:1933–1942.
13. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJJ, Mundt H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med* 2012;**367**:2089–2099.
14. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. *Nat Rev Drug Discov* 2014;**13**:445–464.
15. Landray MJ, Haynes R, Armitage J. Niacin for reduction of cardiovascular risk. *N Engl J Med* 2014;**371**:1943–1944.
16. Zhang X-L, Zhu Q-Q, Zhu L, Chen J-Z, Chen Q-H, Li G-N, Xie J, Kang L-N, Xu B. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med* 2015;**13**:23.
17. Sharma K, Baliga RR. Genetics of dyslipidemia and ischemic heart disease. *Curr Cardiol Rep* 2017;**19**:46.
18. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AF, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett M-S, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki M-L, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee A-H, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WMM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeier J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardisino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. *Lancet* 2012;**380**:572–580.
19. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EPA, Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C, White J, Zabaneh D, Sofat R, McLachlan S, Doevendans PA, Balmforth AJ, Hall AS, North KE, Almqvora B, Hoogeveen RC, Cushman M, Fornage M, Patel SR, Redline S, Siscovick DS, Tsai MY, Karczewski KJ, Hofker MH, Verschuren WM, Bots ML, van der Schouw YT, Melander O, Dominiczak AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters A, Thorand B, Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson JG, Rich SS, de Bakker PIW, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimäki M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP; on behalf of the UCLEB Consortium. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2015;**36**:539–550.
20. Pagonas N, Vlatsas S, Bauer F, Seibert FS, Sasko B, Buschmann I, Ritter O, Kelesidis T, Westhoff TH. The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension. *Eur J Prev Cardiol* 2020;**26**:1301–1309.
21. Rader DJ, deGoma EM. Approach to the patient with extremely low HDL-cholesterol. *J Clin Endocrinol Metab* 2012;**97**:3399–3407.
22. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J* 2017;**38**:2478–2486.
23. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw K-T, Kastelein JJP. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. *J Am Coll Cardiol* 2008;**51**:634–642.
24. Xiang AS, Kingwell BA. Rethinking good cholesterol: a clinicians' guide to understanding HDL. *Lancet Diabetes Endocrinol* 2019;**7**:575–582.
25. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. *Circulation* 1966;**34**:679–697.
26. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. *Lancet* 1975;**1**:16–19.
27. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. *Lancet* 1977;**309**:965–968.
28. Zhong G-C, Huang S-Q, Peng Y, Wan L, Wu Y-Q-L, Hu T-Y, Hu JJ, Hao F-B. High-density lipoprotein cholesterol and all-cause and cause-specific mortality: a dose-response meta-analysis of 37 prospective cohort studies. *Eur J Prev Cardiol* 2020;**27**:1187–1203.
29. Qi Y, Fan J, Liu J, Wang W, Wang M, Sun J, Liu J, Xie W, Zhao F, Li Y, Zhao D. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. *J Am Coll Cardiol* 2015;**65**:355–363.
30. Feng M, Dm Tubeuf E, Cancicio A. Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease. *Eur J Prev Cardiol* 2020.